{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:08:48Z","timestamp":1788901728167,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jaad.2019.12.031","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T11:20:37Z","timestamp":1576840837000},"page":"1271-1281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor\u2013induced dermatologic adverse events"],"prefix":"10.1016","volume":"88","author":[{"given":"Sean","family":"Singer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally Y.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Dewan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaad.2019.12.031_bib1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2019.12.031_bib2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.jaad.2019.12.031_bib3","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jaad.2019.12.031_bib4","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jaad.2019.12.031_bib5","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.clml.2017.07.005","article-title":"Cutaneous adverse events of targeted therapies for hematolymphoid malignancies","volume":"17","author":"Ransohoff","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.031_bib6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.14302","article-title":"Ibrutinib-associated rash: a single-centre experience of clinicopathological features\u00a0and management","volume":"180","author":"Iberri","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.jaad.2019.12.031_bib7","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","article-title":"Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors","volume":"43","author":"Galimont-Collen","year":"2007","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.031_bib8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/1574886314666190522094713","article-title":"Panitumumab induced forearm panniculitis in two women with metastatic colon cancer","volume":"14","author":"Domenico","year":"2019","journal-title":"Curr Drug Saf"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.031_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jdcr.2017.06.035","article-title":"Ibrutinib-associated pityriasis rosea-like rash","volume":"4","author":"Bitar","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2019.12.031_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23775","article-title":"Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia","volume":"90","author":"Mannis","year":"2015","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.031_bib11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"Kamel","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jaad.2019.12.031_bib12","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2019.12.031_bib13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.031_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lungcan.2012.06.009","article-title":"Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials","volume":"78","author":"Petrelli","year":"2012","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.jaad.2019.12.031_bib15","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2019.12.031_bib16","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1542\/peds.2008-2217","article-title":"Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity","volume":"123","author":"Huang","year":"2009","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.jaad.2019.12.031_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju204","article-title":"Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells","volume":"106","author":"Gao","year":"2014","journal-title":"J Natl Cancer Inst"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219333080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219333080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:24:02Z","timestamp":1759274642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219333080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0190962219333080"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.12.031","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor\u2013induced dermatologic adverse events","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}